View larger version (369K):
[in this window]
[in a new window]
|
Figure 1. A 52-year-old man infected with the human immunodeficiency virus (HIV) was treated with zidovudine and lamivudine when his CD4+ lymphocyte count dropped to 105 cells per cubic millimeter and the viral load was 225,000 copies of HIV RNA per milliliter. This treatment was continued for 15 months, but when the viral load tripled, the regimen was changed to highly active antiretroviral therapy consisting of two nucleoside analogues (stavudine and lamivudine) and an HIV-protease inhibitor (indinavir). Within six weeks after the initiation of therapy, the viral load fell to less than 500 copies per milliliter. One year later, . . . [Full Text of this Article] |
Previous
